type a plus sign (+) inside this box
PTO/SB/08A (10-96)
Approved for use through 10/31/99, OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449A/PTO **Application Number** 10/747,994 INFORMATION DISCLOSURE Filing Date 12-30-2003 STATEMENT BY APPLICANT First Named Inventor PARKAR, et al. **Group Art Unit** Not Yet Known (use as many sheets as necessary) Not Yet Known **Examiner Name**

3

of

Sheet

	U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	U.S. Paten Number	t Document Kind Code ² (# known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
BL		5,958,723		Merck Frosst Canada & Co.	09-28-1999	
BL		6,214,972		Merck Frosst Canada & Co.	04-10-2001	
BC		6,395,499		Merck Frosst Canada & Co.	05-28-2002	
						· · · · · · · · · · · · · · · · · · ·
$\overline{}$					 	

Attorney Docket Number

USAV2003/0073 - US - NP

				FOF	REIGN PATENT DOCUMENT	rs		
Examiner		_	Foreign Patent Do	Curnent Kind Code	Name of Patentee or	Date of Publication of Cited Document	Pages, Columns, Lines, Where Relevant	
Initials*	No.1	Office	Number ⁴	(if known)	Applicant of Cited Document	MM-DD-YYYY	Passages or Relevant Figures Appear	T ⁸
BC		wo	96/23066		Merck Frosst Canada Inc.	08-01-1996		
		L.,						

Examiner			Date	
Signature	ه/کر	use	Considered	6.16.06

4

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Э.	€ }	
	3	
	2 6 20 Heast ope a plus sign (+) inside this box →	PTO/SB/08B (10-96)
400	To to use the share agri () made and sox ag	Approved for use through 10/31/99. OMB 0651-0031
7 <i>bu</i>	No.	Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
	Under the Paperwork Reduction Act of 1995, no persons are	e required to respond to a collection of information unless it contains a valid OMB control number.
	A	

Substitute for form 1449B/PTO **INFORMATION DISCLOSURE** STATEMENT BY APPLICANT

Complete if Known **Application Number** 10/747,994 12-30-2003 Filing Date First Named Inventor PARKAR, et al. Not Yet Known Group Art Unit **Examiner Name** Not Yet Known Attorney Docket Number USAV2003/0073 - US - NP

(use as many sheets as necessary)

of Sheet 3 2

	OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
xaminer nitials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	,			
Be		ARIMURA Akinori et al., Prevention Of Allergic Inflammation By A Novel Protaglandin Receptor Antagonist, S-5751, The Journal Of Pharmacology And Experimental Therapeutics, (2001), Vol. 298, No. 2, pp. 411 - 419				
(.		ARMSTRONG Roma A., Platelet Prostanoid Receptors, Pharmacol. Ther., (1996), Vol. 72, No. 3, pp. 171 - 191				
		BRIGHTLING C. E. et al., New Insights Into The Role Of The Mast Cell In Asthma, Clin. Exp. Allergy, (2003), Vol. 33, pp. 550 - 556				
		COLEMAN Robert A. et al., International Union Of Pharmacology Classification Of Prostanoid Receptor: Properties, Distribution, And Structure Of The Receptors And Their Subtypes, Pharmacological Reviews, (1994), Vol. 46, No. 2, pp. 205 - 229				
		DOYLE William J. et al., Physiologic Responses To Intranasal Dose-Response Challenges With Histamine, Methacholine, Bradykinin, And Prostaglandin In Adult Volunteers With And Without Nasal Allergy, Journal Of Allergy And Clinical Immunology, (1990), Vol. 86, pp. 924 - 935				
		HIRATA Masakazu et al., Molecular Characterization Of A Mouse Prostaglanding D Receptor And Functional Expression Of The Cloned Gene, Proc. Nat'l. Acad. Sci. USA, (1994), Vol. 91, pp. 11192 - 11196				
		HOLGATE Stephen T. et al., Bronchial Epithelium As A Key Regulator Of Airway Allergen Sensitization And Remodeling Is Asthma, Am. J. Respir. Crit. Care Med., (2000), Vol. 162, pp. S113 - S117				
		KOBAYASHI Takuya et al., Amino Acid Residues Conferring Ligand Binding Properties Of Prostaglandin I And Prostaglandin D Receptors, The Journal Of Biological Chemistry, (2000), Vol. 276, No. 32, pp. 24294 - 24303				
		LEWIS Robert A. et al., Prostaglandin D2 Generation After Activation Of Rat And Human Mast Cells With Anti-IgE, The Journal Of Immunology, (1982), Vol. 129, No. 4, pp. 1627 - 1631				
$\sqrt{}$		MATSUOKA Toshiyuki et al., Prostaglandin D2 As A Mediator Of Allergic Asthma, Science, (2000), Vol. 287, pp. 2013 - 2019				

Examiner	00110	Date	6.16.06
Signature	Loude	Considered	6.76.08

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial II reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

QIPE ?	c _o
JAN 2 6 2004	ase type a plus sign (+) inside this box ->
Und.	erute Paperwork Reduction Act of 1995, no persons
TRACE'S	Substitute for form 1449B/PTO

PTO/SB/08B (10-96)
Approved for use through 10/31/99, OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of Sheet

Complete if Known			
Application Number	10/747,994		
Filing Date	12-30-2003		
First Named Inventor	PARKAR, et al.		
Group Art Unit	Not Yet Known		
Examiner Name	Not Yet Known	T	
Attorney Docket Number	USAV2003/0073 - US - NP		

	OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²			
Bl		NARUMIYA Shuh et al., Structure And Function Of Prostanoid Receptors, Journal Of Lipid Mediators, (1993), Vol. 6, pp. 155 - 161				
		NEGISHI Manabu et al., Prostanoid Receptors And Their Biological Actions, Prog. Lipid Res., (1993), Vol. 32, No. 4, pp. 417 - 434				
		ROBERTS L. Jackson et al., Increased Production Of Prostaglandin D2 In Patients With Systemic Mastocytosis, The New England Journal Of Medicine, (1980), Vol. 303, No. 24, pp. 1400 - 1404				
V		WRIGHT D. Hamish et al., A Novel Biological Role For Prostaglandin D2 Is Suggested By Distribution Studies Of The Rat DP Prostanoid Receptor, European Journal Of Pharmacology, (1999), Vol. 377, pp. 101 - 115				
		·				
:		•				

-		
Examiner		Date
Signature	Locks	Considered 6 /6 ·06

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.